Conatumumab AMG 655; TRAIL-R2 mAb; Human Anti-TNFRSF10B Recombinant Antibody|cas:896731-82-1|西域试剂

Conatumumab AMG 655; TRAIL-R2 mAb; Human Anti-TNFRSF10B Recombinant Antibody,95.00%

产品编号：Bellancom-P99260| CAS NO：896731-82-1

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99260		￥4600.00	杭州北京（现货）
Bellancom-P99260		￥11500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Conatumumab AMG 655; TRAIL-R2 mAb; Human Anti-TNFRSF10B Recombinant Antibody

产品介绍

Conatumumab (AMG 655) 是一种针对人死亡受体 5 (DR5，TRAILR2) 的单克隆激动剂抗体 (K_d: 长型 DR5 为 1 nM, 短型 DR5 为 0.8 nM)。Conatumumab 通过激活 caspase 诱导细胞凋亡 (apoptosis)。Conatumumab 可用于癌症研究。

生物活性

Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (K_d: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. .

体外研究

Conatumumab (0-10 μg/mL，4 小时) 激活 Colo205、H-2122 和 MiaPaCa2 细胞中的 caspase-3/7。
Conatumumab (0-10 μg/mL，24 小时) 降低敏感肿瘤细胞系 (Colo205、H-2122 和 MiaPaCa2 细胞) 的细胞活力。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Colo205, H-2122, and MiaPaCa2 cells
Concentration:	0-10 μg/mL
Incubation Time:	24 h
Result:	Dose-dependently inhibited cell viability.

体内研究
(In Vivo)

Conatumumab (0-100 μg，腹腔注射，每周两次) 抑制 Colo205、H2122 或 MiaPaCa2/T2 异种移植肿瘤的小鼠的肿瘤生长。
Conatumumab (2.5 μg，i.p.，每周 3 次) 增强化疗药物 (CPT11，HY- 16562) (80 mg/kg) 在 Colo 205 移植瘤中的抗肿瘤活性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors
Dosage:	0, 0.1, 0.3, 1, 3, 10, 30, 100 μg
Administration:	Intraperitoneal injection (i.p.), twice weekly.
Result:	Dose-dependently inhibited tumor growth. Induced caspase-3 activation in tumors (determined by IHC).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors
Dosage:	0, 0.1, 0.3, 1, 3, 10, 30, 100 μg
Administration:	Intraperitoneal injection (i.p.), twice weekly.
Result:	Dose-dependently inhibited tumor growth. Induced caspase-3 activation in tumors (determined by IHC).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors
Dosage:	0, 0.1, 0.3, 1, 3, 10, 30, 100 μg
Administration:	Intraperitoneal injection (i.p.), twice weekly.
Result:	Dose-dependently inhibited tumor growth. Induced caspase-3 activation in tumors (determined by IHC).